All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Atrial fibrillation (AF) is the most common arrhythmia occurring in 2.3--3.4% of the general population and its prevalence is estimated to be at least doubled by 2050 \[[@pone.0170955.ref001]\]. AF represents a major public health problem with a significant impact on cardiovascular morbidity and mortality as well as on health care cost \[[@pone.0170955.ref002],[@pone.0170955.ref003]\]. Glycated hemoglobin (HbA1c) is a reliable biochemical marker of glucose control over the preceding 2--3 months and is widely used in daily clinical practice. The association between HbA1c and AF has been investigated in previous studies but the findings have been controversial \[[@pone.0170955.ref003]--[@pone.0170955.ref007]\]. A recent study from Japan showed that higher HbA1c is associated with a decreased risk of AF \[[@pone.0170955.ref008]\], while the Atherosclerosis Risk in Communities Study showed an increased risk of AF \[[@pone.0170955.ref009]\]. Therefore, we performed a comprehensive meta-analysis to evaluate the current evidence regarding the potential association between HbA1c and AF risk.

Materials and methods {#sec006}
=====================

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement \[[@pone.0170955.ref010]\] was used in this study (detailed in [S1 PRISMA Checklist](#pone.0170955.s001){ref-type="supplementary-material"}).

Literature search strategy and study selection {#sec007}
----------------------------------------------

A literature search of Pubmed and Cochrane Library was performed using the key words ("hemoglobin A, glycosylated" or "glycated hemoglobin" or "hemoglobin A1c" or "HbA1c" or "HgbA1c") and ("atrial fibrillation") from inception to March 2016, with English language restriction. The search was limited to studies carried out in humans only. We reviewed all articles with an abstract suggesting relevance and we checked the reference lists of all relevant articles to identify other eligible studies. Both prospective studies and retrospective studies were included in this meta-analysis. Studies which reported glucose without HbA1c or other types of arrhythmias but no AF (or flutter) were excluded.

Data extraction and quality evaluation {#sec008}
--------------------------------------

The following details were recorded for each study: author, publication year, study design, country of origin, study population, study period/duration of the follow-up, number of subjects, number of events, sex, age, health at baseline, odds ratios (ORs), relative risks (RRs) or hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for HbA1c, and confounding factors adjusted in multivariable analysis. Literature search, data extraction and study quality evaluation were conducted independently by two investigators (W.Q. and N.Z.), with disagreements resolved by a third investigator (T.L.). The Newcastle-Ottawa (Quality Assessment) Scale (NOS) was used to assess bias in included studies.

Statistical analysis {#sec009}
--------------------

In this meta-analysis, the adjusted RRs with 95% CIs were considered as the effect size for all studies, while HRs and ORs were directly deemed equivalent to RRs because of the incidence of AF is rare \[[@pone.0170955.ref011]\]. As the studies included in this meta-analysis used HbA1c level as either a continuous or categorical variable, two separate meta-analyses were performed for both types of variables to evaluate the association between HbA1c levels and AF occurrence. The level of HbA1c was combined into dichotomous variable if there are more than two categories of HbA1c in the studies with HbA1c levels as the categorical variable. Estimates of higher level of HbA1c were pooled with the lower quintile to derive an overall RR, which was subsequently used for pooled analysis.

Weighted random effects model for pooling effect sizes was used. I^2^ and H^2^ statistic were used to test heterogeneity among studies \[[@pone.0170955.ref012]\]. To determine the robustness of the combined estimates, subgroup analyses by country (America vs. not America), year of publication (before 2012 vs. after 2012), sample size (\<3000 participants vs. ≥ 3000 participants), duration of follow-up (\< 96 months vs. ≥ 96 months), age (\<63 years vs.≥ 63 years), quintiles (2 vs. 3 vs. 4), prime effect size (OR vs. RR vs. HR), study quality (quality score ≤ 6 vs. quality score \> 6), and coronary artery bypass grafting (CABG, yes vs. no) were performed. Meta-regression analysis was carried out to identify potential sources of heterogeneity between studies.

Sensitivity analyses excluding those studies in which crude RRs were calculated or had the least number of enrolled patients were performed. Publication bias was assessed using the funnel plots, Begg's and Egger's adjusted rank correlation test. All statistical analyses were conducted with STATA 11 (STATA Corp, College Station, Texas, USA). All reported probabilities were 2-sided with P \< 0.05 considered statistically significant.

Results {#sec010}
=======

Literature search {#sec011}
-----------------

A flow diagram depicting the search and selection process is shown in the [Fig 1](#pone.0170955.g001){ref-type="fig"}. 63 citations were retrieved on the initial search. After removal of 49 citations at the title, abstract level, or full-text assessment, 14 articles were included in our pooled analyses. Specifically, 8 prospective studies and 6 retrospective studies were analyzed.

![Flow chart of selection of studies for inclusion in meta-analysis.\
*From*: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *P*referred *R*eporting *I*tems for *S*ystematic Reviews and *M*eta-*A*nalyses: The PRISMA Statement. PLoS Med 6(6): e1000097. [doi:10.1371/journal.pmed1000097](http://dx.doi.org/doi:10.1371/journal.pmed1000097).](pone.0170955.g001){#pone.0170955.g001}

Study characteristics {#sec012}
---------------------

Baseline characteristics of the 14 included studies are shown in [Table 1](#pone.0170955.t001){ref-type="table"}. These studies included 159,675 participants and 6,340 cases of interest, while the number of participants per study ranged from 101 to 52,448. Of the 14 studies, 6 were conducted in United States, 3 in Japan, 1 in China, 1 in Ireland, 1 in Turkey, 1 in Spain and 1 in 40 countries. Eight studies were published after 2012, while 6 studies were published between 2006 and 2011. Twelve studies recruited both male and female participants, while 2 studies involved only female subjects. Study subjects were aged between 38 and 89 years at baseline with a mean age of 63 years. The follow-up durations of prospective studies ranged from 6 months to 16.4 years and the median was 96 months. Possible confounding factors were adjusted in 10 studies, 7 of which adjusted for age. The mean overall quality score of the studies was 6, with a range of 3--9, and 9 studies had quality scores greater than or equal to 6.

10.1371/journal.pone.0170955.t001

###### Characteristics of prospective and retrospective studies on HbA1c levels and risk of atrial fibrillation.

![](pone.0170955.t001){#pone.0170955.t001g}

  author                  Publication year   country          study population                                                                                        study period(follow-up duration)   participants, N   Events, N   female,%   age, mean(range), years   RR(95%CI)                                               quality score
  ----------------------- ------------------ ---------------- ------------------------------------------------------------------------------------------------------- ---------------------------------- ----------------- ----------- ---------- ------------------------- ------------------------------------------------------- ---------------
  Prospective studies                                                                                                                                                                                                                                                                                                               
  Latini, R               2013               40 countries     White, Black, Asian                                                                                     mean 6.5 y                         8943              613         51.30%     63                        1.10(0.91,1.32)[^a^](#t001fn001){ref-type="table-fn"}   7
  Z.-H. Lu                2014               China            symptomatic PAF with T2DM                                                                               2012--2013 (mean 1y)               149               50          57.72%     62                        1.22(1.02,1.47)[^a^](#t001fn001){ref-type="table-fn"}   6
  Rachel R. Huxley        2012               USA              whites and African-Americans                                                                            1987--2007 (mean 14.5 y)           13025             1311        55.90%     57                        1.11(1.05,1.16)[^a^](#t001fn001){ref-type="table-fn"}   8
  Tobias Schoen           2012               USA              female health professionals                                                                             mean 16.4 y                        34720             835         100%       53(≥45)                   1.06(0.94,1.19)[^a^](#t001fn001){ref-type="table-fn"}   8
  Roopinder K. Sandhu     2014               USA              female health professionals                                                                             mean 16.4 y                        34720             1039        100%       53(≥45)                   1.05(0.86,1.28)[^a^](#t001fn001){ref-type="table-fn"}   8
  Kaoru Matsuura          2009               Japan            diabetic patients who had undergone OPCAB                                                               2000--2007 (mean2.2y)              101               26          20.79%     65                        1.49(0.61,3.64)[^b^](#t001fn002){ref-type="table-fn"}   3
  Omid Fatemi             2014               USA, Canada      volunteers with DM                                                                                      mean 4.68 y                        10,082            159         38%        62(40--79)                0.92(0.67,1.25)[^b^](#t001fn002){ref-type="table-fn"}   5
  C.J. O'Sullivan         2006               Galway,Ireland   people were admitted for emergency and elective vascular surgical procedures                            mean 0.5y                          165               5           41%        72(48--88)                0.21(0.02,1.86)[^b^](#t001fn002){ref-type="table-fn"}   3
  retrospective studies                                                                                                                                                                                                                                                                                                             
  Yasuyuki Iguchi         2010               Japan            Japanese adults in Kurashiki-city companies, offices, government or factories.                          2006--2007                         52448             1161        65.72%     72(65--78)                1.18(1.09,1.28)[^c^](#t001fn003){ref-type="table-fn"}   7
  Takeshi Kinoshita       2011               Japan            patients underwent CABG                                                                                 2002--2010                         805               159         20.25%     68                        0.74(0.60,0.92)[^c^](#t001fn003){ref-type="table-fn"}   6
  Michael E. Halkos       2008               USA              patients underwent CABG                                                                                 2002--2006                         3089              549         27.39%     63                        0.89(0.80,0.98)[^c^](#t001fn003){ref-type="table-fn"}   6
  Turgut, O               2013               Turkey           diabetic patients admitted to cardiology and endocrinology outpatient clinics for routine examination   2011.1--5                          162               81          48.15%     63(38--89)                1.87(0.75,3.01)[^c^](#t001fn003){ref-type="table-fn"}   5
  Maria L Blasco          2014               Spain            patients with AMI and unknown diabetes mellitus                                                         2009--2013                         601               73.00       22%        62                        0.37(0.20,0.67)[^d^](#t001fn004){ref-type="table-fn"}   4
  Sascha Dublin           2010               USA              Treated diabetes                                                                                        mean 8.2 years                     564               253         25.21%     70                        1.14(0.96,1.35)[^c^](#t001fn003){ref-type="table-fn"}   9

^a^Hazard Ratio from the original literature.

^b^Relative Risk generated from the number of atrial fibrillation occurrence in different HbA1c levels.

^c^Odds Ratio from the original literature.

^d^Odds Ratio generated from the number of atrial fibrillation occurrence in different HbA1c levels.

HbA1c and atrial fibrillation {#sec013}
-----------------------------

Of the 14 selected studies, 3 studies \[[@pone.0170955.ref004],[@pone.0170955.ref009],[@pone.0170955.ref013]\] reported that higher HbA1c levels increase the risk of AF, 3 studies \[[@pone.0170955.ref007],[@pone.0170955.ref008],[@pone.0170955.ref014]\] demonstrated that higher HbA1c levels are a protective factor for AF, and the remaining eight studies \[[@pone.0170955.ref005],[@pone.0170955.ref006],[@pone.0170955.ref011],[@pone.0170955.ref015]--[@pone.0170955.ref019]\] showed no significant association between HbA1c levels and AF.

In the primary meta-analysis, HbA1c levels were not associated with an increased risk for AF both as a continuous variable (RR, 1.06; 95% CI, 0.96--1.18) with significant heterogeneity (H^2^ = 5.15 and I^2^, 80.6%; 95% CI, 62.5%-89.9%; [Fig 2](#pone.0170955.g002){ref-type="fig"}) as well as a categorical variable (RR, 0.99; 95% CI, 0.83--1.18) with significant heterogeneity (H^2^ = 2.93 and I^2^, 65.9%; 95% CI, 23.6%-84.8%; [Fig 3](#pone.0170955.g003){ref-type="fig"}). However, prospective studies showed nearly 10% increased risk of AF with increased HbA1c levels, both as a continuous variable (RR, 1.11; 95% CI, 1.06--1.16) without significant heterogeneity (H^2^ = 0.53 and I^2^, 0.0%; 95% CI, 0.0%-89.6%; [Fig 2](#pone.0170955.g002){ref-type="fig"}) and as a categorical variable (RR, 1.09; 95% CI, 1.00--1.18) without significant heterogeneity (H^2^ = 1.07 and I^2^, 6.7%; 95% CI, 0.0%-76.3%; [Fig 3](#pone.0170955.g003){ref-type="fig"}). We also performed analyses among diabetic patients and non-diabetic patients, but there was not statistically significant association between HbA1c and AF. The pooled RR for higher HbA1c levels compared with lower HbA1c levels was 1.09 (95% CI: 0.79, 1.51) and 0.82 (95% CI: 0.43, 1.55) among diabetic and non-diabetic patients, respectively.

![Forest plot demonstrating the association between HbA1c levels and AF depending on different study styles which HbA1c levels were analyzed as continuous variable.\
Relative risks of AF for higher HbA1c compared with lower HbA1c. Squares indicate study-specific risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance); horizontal lines indicate 95% CIs; diamond indicates summary risk estimate with its corresponding 95% CI.](pone.0170955.g002){#pone.0170955.g002}

![Forest plot demonstrating the association between HbA1c levels and AF depending on different study styles which HbA1c levels were analyzed as categorical variable.\
Relative risks of AF for higher HbA1c compared with lower HbA1c. Squares indicate study-specific risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance); horizontal lines indicate 95% CIs; diamond indicates summary risk estimate with its corresponding 95% CI.](pone.0170955.g003){#pone.0170955.g003}

Relative risks of AF for higher HbA1c compared with lower HbA1c. Squares indicate study-specific risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance); horizontal lines indicate 95% CIs; diamond indicates summary risk estimate with its corresponding 95% CI.

Relative risks of AF for higher HbA1c compared with lower HbA1c. Squares indicate study-specific risk estimates (size of the square reflects the study-specific statistical weight, that is, the inverse of the variance); horizontal lines indicate 95% CIs; diamond indicates summary risk estimate with its corresponding 95% CI.

Subgroup and sensitivity analyses {#sec014}
---------------------------------

Subgroup, meta-regression and sensitivity analyses were performed to identify the origin of heterogeneity in the studies included.

To explore the heterogeneity among these studies, subgroup analyses were performed based on a number of key study characteristics. When analyzing studies using the HbA1c levels as a continuous variable, the effects of higher HbA1c on AF varied significantly across study design, publication year, follow-up duration, age and CABG ([Table 2](#pone.0170955.t002){ref-type="table"}). Increased AF risk was observed in patients with higher HbA1c levels in studies which i) were prospective, ii) were published after 2012, iii) had longer follow-up duration, iv) included subjects aged \< 63 years, v) concerned with prime effect size HR, and vi) excluded post-CABG AF. In addition, no heterogeneity was evident in these subgroup analyses (P \> 0.05). We also performed subgroup analyses for several key study characteristics among studies using the HbA1c levels as a categorical variable. We demonstrated that higher HbA1c predicted the development of AF in prospective studies, in those conducted in the United States, in studies with longer follow-up (more than 96 months), and in those with larger sample size, in those with prime effect size HR, and in studies with higher quality score (≥6) ([Table 3](#pone.0170955.t003){ref-type="table"}).

10.1371/journal.pone.0170955.t002

###### Stratified analyses of pooled relative risks (95% CI) of AF for HbA1c levels as continuous variable.

![](pone.0170955.t002){#pone.0170955.t002g}

  ---------------------------------------------------------------------------------------------------------------
  Stratified analyses                        No. of studies   Pooled RR(95% CI)     Heterogeneity test   
  ------------------------------------------ ---------------- --------------------- -------------------- --------
  style                                                                                                  

  prospective                                3                **1.11(1.06,1.16)**   0.59                 0.00%

  retrospective                              5                1.02(0.84,1.24)       \<0.01               87.50%

  Country                                                                                                

  America                                    3                1.04(0.89,1.21)       \<0.01               86.60%

  Not America                                4                1.09(0.85,1.41)       \<0.01               84.10%

  Publication year                                                                                       

  before 2011                                4                0.98(0.80,1.20)       \<0.01               89.80%

  After 2012                                 4                **1.20(1.06,1.19)**   0.36                 5.70%

  Sample size                                                                                            

  \<3000                                     4                1.09(0.82,1.44)       \<0.01               81.70%

  ≥3000\>ze7H耂\                             4                1.06(0.96,1.18)       \<0.01               84.60%
  ≥96m\>ez7I耂\                                                                                          
  ≥6\>ez71.13(1.09,1.18)J耀\                                                                             
  1.13(1.09,1.18)70.                                                                                     

  Follow-up duration                                                                                     

  \<96m                                      2                **1.16(1.02,1.32)**   0.43                 0.00%

  ≥96m\>ez7I耂\                              1                **1.11(1.05,1.16)**   .                    .
  ≥6\>ez71.13(1.09,1.18)J耀\                                                                             
  1.13(1.09,1.18)70.83(                                                                                  

  age                                                                                                    

  \<63y                                      2                **1.12(1.06,1.18)**   0.31                 4.30%

  ≥63y                                       6                1.03(0.88,1.22)       \<0.01               84.60%

  prime effect size                                                                                      

  OR                                         5                1.02(0.84,1.24)       \<0.01               87.50%

  RR                                         0                .                     .                    .

  HR                                         3                **1.11(1.06,1.16)**   0.59                 0.00%

  CABG                                                                                                   

  Yes                                        2                **0.83(0.70,0.99)**   0.13                 57.20%

  No                                         6                **1.13(1.09,1.18)**   0.46                 0.00%

  Study quality                                                                                          

  \<6                                        1                1.87(0.93,3.76)       .                    .

  ≥6\>ez71.13(1.09,1.18)J耀\                 7                1.05(0.95,1.16)       \<0.01               82.20%
  1.13(1.09,1.18)70.83(0.70,0.99)K耀0.83(0                                                               
  ---------------------------------------------------------------------------------------------------------------

Note: I^2^ is interpreted as the proportion of total variation across studies that is due to heterogeneity rather than chance; CABG, coronary artery bypass grafting.

10.1371/journal.pone.0170955.t003

###### Stratified analyses of pooled relative risks (95% CI) of AF for HbA1c levels as categorical variable.
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  ------------------------------------------------------------------------------------------------------------------
  Stratified analyses                           No. of studies   Pooled RR(95% CI)     Heterogeneity test   
  --------------------------------------------- ---------------- --------------------- -------------------- --------
  style                                                                                                     

  prospective                                   6                **1.09(1.00,1.18)**   0.37                 6.70%

  retrospective                                 1                **0.37(0.20,0.67)**   .                    .

  Country                                                                                                   

  America                                       4                **1.09(1.01,1.17)**   0.44                 0.00%

  Not America                                   3                0.57(0.18,1.77)       0.03                 72.30%

  Publication year                                                                                          

  before 2011                                   2                0.73(0.12,4.59)       0.10                 62.20%

  After 2012                                    5                0.99(0.83,1.18)       \<0.01               73.20%

  Sample size                                                                                               

  \<3000                                        3                0.57(0.18,1.77)       0.03                 72.30%

  ≥3000\>ze7H耂\                                4                **1.09(1.01,1.17)**   0.44                 0.00%
  ≥96m\>ez7I耂\                                                                                             
  ≥6\>ez71.13(1.09,1.18)J耀1.13(1.09,1.18)70.                                                               

  Follow-up duration                                                                                        

  \<96m                                         3                0.95(0.56,1.63)       0.24                 29.70%

  ≥96m\>ez7I耂\                                 3                **1.10(1.02,1.19)**   0.48                 0.00%
  ≥6\>ez71.13(1.09,1.18)J耀\                                                                                
  1.13(1.09,1.18)70.83(                                                                                     

  age                                                                                                       

  \<63y                                         5                0.99(0.83,1.18)       \<0.01               73.20%

  ≥63y                                          2                0.73(0.12,4.59)       0.10                 62.20%

  quintiles                                                                                                 

  2                                             3                0.95(0.56,1.63)       0.24                 29.70%

  3                                             2                0.68(0.22,2.11)       \<0.01               92.60%

  4                                             2                1.05(0.95,1.17)       0.96                 0.00%

  prime effect size                                                                                         

  OR                                            1                **0.37(0.20,0.67)**   .                    .

  RR                                            3                0.95(0.56,1.63)       0.24                 29.70%

  HR                                            3                **1.10(1.02,1.19)**   0.48                 0.00%

  Adjustment for CABG                                                                                       

  Yes                                           1                1.49(0.61,3.64)       .                    .

  No                                            6                0.98(0.82,1.17)       \<0.01               70.70%

  Study quality                                                                                             

  \<6                                           4                0.69(0.35,1.36)       0.02                 71.00%

  ≥6                                            3                **1.10(1.02,1.19)**   0.48                 0.00%
  ------------------------------------------------------------------------------------------------------------------

Note: I^2^ is interpreted as the proportion of total variation across studies that is due to heterogeneity rather than chance; CABG, coronary artery bypass grafting.

In the meta-regression analysis of all 14 studies, the influence of study design, country of origin, publication year, sample size, CABG setting, and study quality on heterogeneity were explored. None of these parameters contributed significantly to substantial heterogeneity (P \> 0.05).

We further performed sensitivity analyses as follows. Of the 8 studies that analyzed HbA1c levels as continuous variable, and after excluding the study by Turgut \[[@pone.0170955.ref016]\], which had the least number of enrolled patients, sensitivity analysis did not reveal significant influence on overall results (RR, 1.05; 95% CI, 0.95--1.16); with significant heterogeneity (I^2^, 82.2%; 95% CI, 64.4%-91.1%). Of the 7 studies using HbA1c level as categorical variable, only 3 studies reported multivariable adjusted RRs on AF for higher HbA1c compared with lower HbA1c levels. After removing the study without multivariable adjusted RRs, significant difference was not found in the heterogeneity among the remaining 3 studies (I^2^, 0.0%; 95% CI, 0.0%-89.6%) and the results were the same as the prospective cohort studies (RR, 1.10; 95% CI, 1.02--1.19).

Publication bias {#sec015}
----------------

Neither funnel plots (Figs [4](#pone.0170955.g004){ref-type="fig"} and [5](#pone.0170955.g005){ref-type="fig"}) nor Egger's and Begg's tests revealed evidence of publication bias (p = 0.81 for Begg's test and p = 0.80 for Egger's test in the studies using HbA1c levels as continuous variable; p = 0.29 with Begg's test and p = 0.13 with Egger's test in the studies using HbA1c levels as categorical variable).

![Funnel plots of continuous variable results included in meta-analysis.](pone.0170955.g004){#pone.0170955.g004}

![Funnel plots of categorical variable results included in meta-analysis.](pone.0170955.g005){#pone.0170955.g005}

Discussion {#sec016}
==========

In this comprehensive meta-analysis, we demonstrated that increased HbA1c levels were associated with an increased risk of AF in prospective cohort studies but not in case-control studies. A recent study from Eastern Norway indicated a significant positive correlation between HbA1c levels and duration of AF (r = 0.408, p = 0.005), thereby implicating abnormal glucose metabolism in increasing AF burden \[[@pone.0170955.ref020]\]. Given that diabetes increases thromboembolic risk in AF and further promotes the arrhythmia, HbA1c levels could be a useful marker in strategies aiming to reduce AF burden and its related complications. In support of this notion, Saliba et al. recently showed that glycated hemoglobin is directly associated with stroke risk, and the use of HbA1c improved accuracy for predicting stroke events in diabetic patients with AF \[[@pone.0170955.ref021]\]. Based on retrospective data with the effect size of standardized mean difference (SMDs) mostly among Chinese subjects, Yang et al. demonstrated elevated HbA1c levels could increase the risk of AF in patients with diabetes mellitus (DM) \[[@pone.0170955.ref022]\]. We further investigated this in the general population with the effect size of RRs, both based on prospective and retrospective studies conducted globally.

We also performed subgroup analyses examining potentially significant factors such as publication year, sample size, age, geographical origin, and study quality that may affect the authenticity of the potential association between HbA1c levels and AF development. Thus, we showed that studies conducted in the United States, studies published after 2012, those with longer follow-up duration, studies with larger sample size, those with higher quality score and those not examining postoperative AF had significant influence on our results, implying that these factors may be the source of the heterogeneity.

Poor glycemic control reflected by increased HbA1c levels is an independent risk factor of AF \[[@pone.0170955.ref023]\]. Several underlying pathophysiological mechanisms have been proposed to explain this association. Firstly, as a long half-life protein, HbA1c has been suggested as reliable tool not only for diagnosing DM but also for identifying individuals at increased risk for cardiovascular events whether or not DM is present \[[@pone.0170955.ref024],[@pone.0170955.ref025]\]. High levels of HbA1c were associated not only with the long-term disorder of glycolipid metabolism but also with low-grade systematic inflammation and the progression of atherosclerotic disease \[[@pone.0170955.ref026]\]. In a population study, high HbA1c levels have been associated with biomarkers of systemic inflammation such as C-reactive protein (CRP), D-dimer, uric acid, white blood cell count and fibrinogen \[[@pone.0170955.ref027]\]. Of note, inflammation and oxidative stress have been associated with AF development \[[@pone.0170955.ref028]\]. Moreover, overexpression of collagen proteins might contribute to the prolongation of the atrial activation time and cycle length, and to the reduction of atrial voltage, which create a substrate for the development and perpetuation of AF \[[@pone.0170955.ref029]\]. Therefore, increased HbA1c levels might be involved in the inflammatory state implicated in AF pathophysiology.

Study limitations {#sec017}
-----------------

We acknowledge several limitations of our study. Firstly, despite the lack of indication of major publication bias in the formal evaluations employed, potential publication bias cannot be completely excluded. This may be responsible for some heterogeneity and underpowered meta-regression, especially in the light of the small number of studies. Secondly, since we focused on the serum levels of HbA1c more frequently, a subset of well-controlled diabetic patients are at an increased risk of AF could be misclassified into the low serum levels group, especially in case-control studies. Besides, when the level of HbA1c was analyzed as a categorical variable, the RRs were combined into dichotomous variable if more than two groups of RRs were present. Moreover, the thresholds of HbA1c levels were different across the included studies. Nevertheless, no significant difference was found among different quintiles of RRs and the cutoff points were similar between 5.7% to 7.0%. In addition, both retrospective and prospective studies were pooled together and different statistical parameters like RR, OR, HR were treated as equivalent for analysis purposes. The differences among different prime effect sizes may be due to study style. Some AF patients did not visit hospital regularly and some AF cases might have been undetected because many AF episodes were asymptomatic, which might underestimate of AF. Indeed, the only way to obtain a true picture of AF prevalence would be the use of long-term ECG or Holter monitoring.

Conclusions {#sec018}
===========

This comprehensive meta-analysis suggests that elevated serum HbA1c levels were associated with an increased risk of AF in prospective studies, and therefore serum HbA1c levels may be viewed as a potential biomarker to predict AF and as a tool for AF prevention. Undoubtedly, further prospective studies with larger population sizes are needed to elucidate the exact prognostic role of HbA1c in AF development. Finally, the use of HbA1c levels as a prognostic and monitoring tool in the management of AF as well as its related complications should be evaluated carefully.
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